Key result
Case report evaluates IV thrombolysis feasibility and intracranial hemorrhage risk in rivaroxaban-treated acute ischemic stroke.
Why the study?
Effective anticoagulation is a contraindication for intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke, and the clinical outcome and risk of symptomatic intracranial hemorrhage after intravenous thrombolysis in stroke patients receiving rivaroxaban were previously unknown.
Case Report (n=1)
Rivaroxaban, a novel direct factor Xa inhibitor with consistent anticoagulant properties, was found to be safer and equally effective as warfarin in the prevention of embolic stroke in patients with nonvalvular atrial fibrillation [1, 2] . Effective anticoagulation predisposes to bleeding and represents a contraindication for intravenous thrombolysis (IVT) with recom-binant tissue plasminogen activator (rtPA), the only approved therapy for acute ischemic stroke [3] . However, the clinical outcome and the risk of symptomatic intracranial hemor-rhage (ICH) after IVT in stroke patients treated with rivaroxaban have so far been unknown.
No takes yet. Share an insight, caveat, or question.
Fluri et al. (2013) conducted a case report in Acute ischemic stroke in a patient receiving rivaroxaban (n=1). Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) while receiving rivaroxaban was evaluated on Clinical outcome and symptomatic intracranial hemorrhage (ICH). Intravenous thrombolysis with rtPA was evaluated for clinical outcome and symptomatic intracranial hemorrhage risk in an acute ischemic stroke patient treated with rivaroxaban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: